Editas Medicine ( (EDIT) ) has issued an update.
On March 18, 2025, Editas Medicine announced the resignation of Erick Lucera, its Executive Vice President and Chief Financial Officer, effective March 28, 2025. Amy Parison, who has been with the company since January 2025, will succeed him, bringing extensive experience from her previous roles at Rubius Therapeutics and Vertex Pharmaceuticals. The transition includes new compensation terms for Ms. Parison, highlighting her strategic importance to the company.
More about Editas Medicine
Editas Medicine, Inc. operates in the biotechnology industry, focusing on developing genome editing technologies and therapies.
YTD Price Performance: 6.11%
Average Trading Volume: 4,036,139
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $109.1M
For an in-depth examination of EDIT stock, go to TipRanks’ Stock Analysis page.